We are analyzing https://link.springer.com/article/10.1186/bcr2602.

Title:
Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells | Breast Cancer Research
Description:
Introduction The HIV protease inhibitor nelfinavir is currently under investigation as a new anti-cancer drug. Several studies have shown that nelfinavir induces cell cycle arrest, endoplasmic reticulum stress, autophagy, and apoptosis in cancer cells. In the present article, the effect of nelfinavir on human breast cancer cells is examined and potential combination treatments are investigated. Methods The effects of nelfinavir and tamoxifen on the human breast cancer cell lines MCF7, T47 D, MDA-MB-453, and MDA-MB-435 were tested by analysing their influence on cell viability (via 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay), apoptosis (annexin binding, poly(ADP-ribose) polymerase cleavage), autophagy (autophagy marker light chain 3B expression), endoplasmic reticulum stress (binding protein and activating transcription factor 3 expression), and the occurrence of oxidative stress (intracellular glutathione level). Results Nelfinavir induced apoptosis in all four breast cancer cell lines tested, although the extent of autophagy and endoplasmic reticulum stress varied among the cell lines. The concentration of nelfinavir needed for an efficient induction of apoptosis in breast cancer cells could be reduced from 15 μg/ml to 6 μg/ml when combined with tamoxifen. At a concentration of 6 μg/ml, tamoxifen substantially enhanced the endoplasmic reticulum stress reaction in those cell lines that responded to nelfinavir with binding protein (BiP) upregulation (MCF7, T47D), and enhanced autophagy in cell lines that responded to nelfinavir treatment with autophagy marker light chain 3B upregulation (MDA-MB-453). Although tamoxifen has been described to be able to induce oxidative stress at concentrations similar to those applied in this study (6 μg/ml), we observed that nelfinavir but not tamoxifen reduced the intracellular glutathione level of breast cancer cells within hours of application by up to 32%, suggesting the induction of oxidative stress was an early event and an additional cause of the apoptosis induced by nelfinavir. Conclusions The results demonstrate that nelfinavir may be an effective drug against breast cancer and could be combined with tamoxifen to enhance its efficacy against breast cancer cells. Moreover, the cytotoxic effect of a tamoxifen and nelfinavir combination was independent of the oestrogen receptor status of the analysed breast cancer cells, suggesting a potential benefit of a combination of these two drugs even in patients with no hormone-responsive tumours. We therefore recommend that clinical studies on nelfinavir with breast cancer patients should include this drug combination to analyse the therapeutic efficacy as well as the safety and tolerability of this potential treatment option.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Science
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

nelfinavir, cells, cancer, cell, breast, tamoxifen, article, figure, pubmed, google, scholar, stress, mdamb, glutathione, cas, μgml, combination, apoptosis, mcf, endoplasmic, effect, lines, reticulum, concentrations, effects, akt, treatment, observed, autophagy, oestrogen, drugs, activity, protein, hours, analysed, levels, protease, assay, culture, germany, incubated, hiv, inhibitor, drug, reduced, death, authors, intracellular, proteasome, analysis,

Topics {✒️}

extracellular signal-regulated kinase endoplasmic reticulum-induced stress stress-induced cell damage perk/eif2α/atf4 module chromogenic bcip/nbt assay hormone receptor-independent effects 5-diphenyl-2h-tetrazolium bromide signaling regulator grp78/bip trypan blue-excluding cells full size image article download pdf tamoxifen-induced adduct formation pleiotropic anti-cancer effects oestrogen receptor-negative erk1/2-mediated mcl-1 stabilization alkaline phosphatase-coupled antibodies cell survival-related proteins ludwig-maximilians-university munich lower lc3b-ii band cell-protective mechanism oestrogen receptor-positive hormone receptor status german research foundation mda-mb-435 cells survived klaus friese & alexander burges cell signaling technology cell cycle retardation synergistic anti-tumour effects anti-apoptotic mcl-1 protein alkaline phosphatase detection sorafenib-mediated mcl-1 downregulation endoplasmic reticulum stress breast cancer patients bioluminescent proteasome assay node-negative patients akt-1 mediates survival full access hiv protease inhibitors mek1/erk pathways 5 mm n-acetyl-cysteine oestrogen receptor status cell lines respond hiv protease inhibitor hiv-infected persons breast cancer cells related subjects pi3k/akt pathway inhibition potential negative interaction nelfinavir-treated mda-mb-453 privacy choices/manage cookies

Questions {❓}

Chow WA, Jiang C, Guan M: Anti-HIV drugs for cancer therapeutics: back to the future?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells
         description:The HIV protease inhibitor nelfinavir is currently under investigation as a new anti-cancer drug. Several studies have shown that nelfinavir induces cell cycle arrest, endoplasmic reticulum stress, autophagy, and apoptosis in cancer cells. In the present article, the effect of nelfinavir on human breast cancer cells is examined and potential combination treatments are investigated. The effects of nelfinavir and tamoxifen on the human breast cancer cell lines MCF7, T47 D, MDA-MB-453, and MDA-MB-435 were tested by analysing their influence on cell viability (via 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay), apoptosis (annexin binding, poly(ADP-ribose) polymerase cleavage), autophagy (autophagy marker light chain 3B expression), endoplasmic reticulum stress (binding protein and activating transcription factor 3 expression), and the occurrence of oxidative stress (intracellular glutathione level). Nelfinavir induced apoptosis in all four breast cancer cell lines tested, although the extent of autophagy and endoplasmic reticulum stress varied among the cell lines. The concentration of nelfinavir needed for an efficient induction of apoptosis in breast cancer cells could be reduced from 15 μg/ml to 6 μg/ml when combined with tamoxifen. At a concentration of 6 μg/ml, tamoxifen substantially enhanced the endoplasmic reticulum stress reaction in those cell lines that responded to nelfinavir with binding protein (BiP) upregulation (MCF7, T47D), and enhanced autophagy in cell lines that responded to nelfinavir treatment with autophagy marker light chain 3B upregulation (MDA-MB-453). Although tamoxifen has been described to be able to induce oxidative stress at concentrations similar to those applied in this study (6 μg/ml), we observed that nelfinavir but not tamoxifen reduced the intracellular glutathione level of breast cancer cells within hours of application by up to 32%, suggesting the induction of oxidative stress was an early event and an additional cause of the apoptosis induced by nelfinavir. The results demonstrate that nelfinavir may be an effective drug against breast cancer and could be combined with tamoxifen to enhance its efficacy against breast cancer cells. Moreover, the cytotoxic effect of a tamoxifen and nelfinavir combination was independent of the oestrogen receptor status of the analysed breast cancer cells, suggesting a potential benefit of a combination of these two drugs even in patients with no hormone-responsive tumours. We therefore recommend that clinical studies on nelfinavir with breast cancer patients should include this drug combination to analyse the therapeutic efficacy as well as the safety and tolerability of this potential treatment option.
         datePublished:2010-07-01T00:00:00Z
         dateModified:2010-07-01T00:00:00Z
         pageStart:1
         pageEnd:11
         license:http://creativecommons.org/licenses/by/2.0/
         sameAs:https://doi.org/10.1186/bcr2602
         keywords:
            Breast Cancer Cell
            Tamoxifen
            MCF7 Cell
            Endoplasmic Reticulum Stress
            Breast Cancer Cell Line
            Cancer Research
            Oncology
            Surgical Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2602/MediaObjects/13058_2010_2563_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2602/MediaObjects/13058_2010_2563_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2602/MediaObjects/13058_2010_2563_Fig3_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2602/MediaObjects/13058_2010_2563_Fig4_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2602/MediaObjects/13058_2010_2563_Fig5_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2602/MediaObjects/13058_2010_2563_Fig6_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2602/MediaObjects/13058_2010_2563_Fig7_HTML.jpg
         isPartOf:
            name:Breast Cancer Research
            issn:
               1465-542X
            volumeNumber:12
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Ansgar Brüning
               affiliation:
                     name:Ludwig-Maximilians-University Munich
                     address:
                        name:Department of Obstetrics and Gynaecology, Campus Innenstadt, Ludwig-Maximilians-University Munich, Munich, Germany
                        type:PostalAddress
                     type:Organization
                     name:Ludwig-Maximilians-University Munich
                     address:
                        name:Department of Obstetrics and Gynaecology, Campus Grosshadern, Ludwig-Maximilians-University Munich, Munich, Germany
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Klaus Friese
               affiliation:
                     name:Ludwig-Maximilians-University Munich
                     address:
                        name:Department of Obstetrics and Gynaecology, Campus Innenstadt, Ludwig-Maximilians-University Munich, Munich, Germany
                        type:PostalAddress
                     type:Organization
                     name:Ludwig-Maximilians-University Munich
                     address:
                        name:Department of Obstetrics and Gynaecology, Campus Grosshadern, Ludwig-Maximilians-University Munich, Munich, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Alexander Burges
               affiliation:
                     name:Ludwig-Maximilians-University Munich
                     address:
                        name:Department of Obstetrics and Gynaecology, Campus Grosshadern, Ludwig-Maximilians-University Munich, Munich, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ioannis Mylonas
               affiliation:
                     name:Ludwig-Maximilians-University Munich
                     address:
                        name:Department of Obstetrics and Gynaecology, Campus Innenstadt, Ludwig-Maximilians-University Munich, Munich, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells
      description:The HIV protease inhibitor nelfinavir is currently under investigation as a new anti-cancer drug. Several studies have shown that nelfinavir induces cell cycle arrest, endoplasmic reticulum stress, autophagy, and apoptosis in cancer cells. In the present article, the effect of nelfinavir on human breast cancer cells is examined and potential combination treatments are investigated. The effects of nelfinavir and tamoxifen on the human breast cancer cell lines MCF7, T47 D, MDA-MB-453, and MDA-MB-435 were tested by analysing their influence on cell viability (via 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay), apoptosis (annexin binding, poly(ADP-ribose) polymerase cleavage), autophagy (autophagy marker light chain 3B expression), endoplasmic reticulum stress (binding protein and activating transcription factor 3 expression), and the occurrence of oxidative stress (intracellular glutathione level). Nelfinavir induced apoptosis in all four breast cancer cell lines tested, although the extent of autophagy and endoplasmic reticulum stress varied among the cell lines. The concentration of nelfinavir needed for an efficient induction of apoptosis in breast cancer cells could be reduced from 15 μg/ml to 6 μg/ml when combined with tamoxifen. At a concentration of 6 μg/ml, tamoxifen substantially enhanced the endoplasmic reticulum stress reaction in those cell lines that responded to nelfinavir with binding protein (BiP) upregulation (MCF7, T47D), and enhanced autophagy in cell lines that responded to nelfinavir treatment with autophagy marker light chain 3B upregulation (MDA-MB-453). Although tamoxifen has been described to be able to induce oxidative stress at concentrations similar to those applied in this study (6 μg/ml), we observed that nelfinavir but not tamoxifen reduced the intracellular glutathione level of breast cancer cells within hours of application by up to 32%, suggesting the induction of oxidative stress was an early event and an additional cause of the apoptosis induced by nelfinavir. The results demonstrate that nelfinavir may be an effective drug against breast cancer and could be combined with tamoxifen to enhance its efficacy against breast cancer cells. Moreover, the cytotoxic effect of a tamoxifen and nelfinavir combination was independent of the oestrogen receptor status of the analysed breast cancer cells, suggesting a potential benefit of a combination of these two drugs even in patients with no hormone-responsive tumours. We therefore recommend that clinical studies on nelfinavir with breast cancer patients should include this drug combination to analyse the therapeutic efficacy as well as the safety and tolerability of this potential treatment option.
      datePublished:2010-07-01T00:00:00Z
      dateModified:2010-07-01T00:00:00Z
      pageStart:1
      pageEnd:11
      license:http://creativecommons.org/licenses/by/2.0/
      sameAs:https://doi.org/10.1186/bcr2602
      keywords:
         Breast Cancer Cell
         Tamoxifen
         MCF7 Cell
         Endoplasmic Reticulum Stress
         Breast Cancer Cell Line
         Cancer Research
         Oncology
         Surgical Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2602/MediaObjects/13058_2010_2563_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2602/MediaObjects/13058_2010_2563_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2602/MediaObjects/13058_2010_2563_Fig3_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2602/MediaObjects/13058_2010_2563_Fig4_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2602/MediaObjects/13058_2010_2563_Fig5_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2602/MediaObjects/13058_2010_2563_Fig6_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2602/MediaObjects/13058_2010_2563_Fig7_HTML.jpg
      isPartOf:
         name:Breast Cancer Research
         issn:
            1465-542X
         volumeNumber:12
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Ansgar Brüning
            affiliation:
                  name:Ludwig-Maximilians-University Munich
                  address:
                     name:Department of Obstetrics and Gynaecology, Campus Innenstadt, Ludwig-Maximilians-University Munich, Munich, Germany
                     type:PostalAddress
                  type:Organization
                  name:Ludwig-Maximilians-University Munich
                  address:
                     name:Department of Obstetrics and Gynaecology, Campus Grosshadern, Ludwig-Maximilians-University Munich, Munich, Germany
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Klaus Friese
            affiliation:
                  name:Ludwig-Maximilians-University Munich
                  address:
                     name:Department of Obstetrics and Gynaecology, Campus Innenstadt, Ludwig-Maximilians-University Munich, Munich, Germany
                     type:PostalAddress
                  type:Organization
                  name:Ludwig-Maximilians-University Munich
                  address:
                     name:Department of Obstetrics and Gynaecology, Campus Grosshadern, Ludwig-Maximilians-University Munich, Munich, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Alexander Burges
            affiliation:
                  name:Ludwig-Maximilians-University Munich
                  address:
                     name:Department of Obstetrics and Gynaecology, Campus Grosshadern, Ludwig-Maximilians-University Munich, Munich, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ioannis Mylonas
            affiliation:
                  name:Ludwig-Maximilians-University Munich
                  address:
                     name:Department of Obstetrics and Gynaecology, Campus Innenstadt, Ludwig-Maximilians-University Munich, Munich, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research
      issn:
         1465-542X
      volumeNumber:12
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Ludwig-Maximilians-University Munich
      address:
         name:Department of Obstetrics and Gynaecology, Campus Innenstadt, Ludwig-Maximilians-University Munich, Munich, Germany
         type:PostalAddress
      name:Ludwig-Maximilians-University Munich
      address:
         name:Department of Obstetrics and Gynaecology, Campus Grosshadern, Ludwig-Maximilians-University Munich, Munich, Germany
         type:PostalAddress
      name:Ludwig-Maximilians-University Munich
      address:
         name:Department of Obstetrics and Gynaecology, Campus Innenstadt, Ludwig-Maximilians-University Munich, Munich, Germany
         type:PostalAddress
      name:Ludwig-Maximilians-University Munich
      address:
         name:Department of Obstetrics and Gynaecology, Campus Grosshadern, Ludwig-Maximilians-University Munich, Munich, Germany
         type:PostalAddress
      name:Ludwig-Maximilians-University Munich
      address:
         name:Department of Obstetrics and Gynaecology, Campus Grosshadern, Ludwig-Maximilians-University Munich, Munich, Germany
         type:PostalAddress
      name:Ludwig-Maximilians-University Munich
      address:
         name:Department of Obstetrics and Gynaecology, Campus Innenstadt, Ludwig-Maximilians-University Munich, Munich, Germany
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Ansgar Brüning
      affiliation:
            name:Ludwig-Maximilians-University Munich
            address:
               name:Department of Obstetrics and Gynaecology, Campus Innenstadt, Ludwig-Maximilians-University Munich, Munich, Germany
               type:PostalAddress
            type:Organization
            name:Ludwig-Maximilians-University Munich
            address:
               name:Department of Obstetrics and Gynaecology, Campus Grosshadern, Ludwig-Maximilians-University Munich, Munich, Germany
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Klaus Friese
      affiliation:
            name:Ludwig-Maximilians-University Munich
            address:
               name:Department of Obstetrics and Gynaecology, Campus Innenstadt, Ludwig-Maximilians-University Munich, Munich, Germany
               type:PostalAddress
            type:Organization
            name:Ludwig-Maximilians-University Munich
            address:
               name:Department of Obstetrics and Gynaecology, Campus Grosshadern, Ludwig-Maximilians-University Munich, Munich, Germany
               type:PostalAddress
            type:Organization
      name:Alexander Burges
      affiliation:
            name:Ludwig-Maximilians-University Munich
            address:
               name:Department of Obstetrics and Gynaecology, Campus Grosshadern, Ludwig-Maximilians-University Munich, Munich, Germany
               type:PostalAddress
            type:Organization
      name:Ioannis Mylonas
      affiliation:
            name:Ludwig-Maximilians-University Munich
            address:
               name:Department of Obstetrics and Gynaecology, Campus Innenstadt, Ludwig-Maximilians-University Munich, Munich, Germany
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Obstetrics and Gynaecology, Campus Innenstadt, Ludwig-Maximilians-University Munich, Munich, Germany
      name:Department of Obstetrics and Gynaecology, Campus Grosshadern, Ludwig-Maximilians-University Munich, Munich, Germany
      name:Department of Obstetrics and Gynaecology, Campus Innenstadt, Ludwig-Maximilians-University Munich, Munich, Germany
      name:Department of Obstetrics and Gynaecology, Campus Grosshadern, Ludwig-Maximilians-University Munich, Munich, Germany
      name:Department of Obstetrics and Gynaecology, Campus Grosshadern, Ludwig-Maximilians-University Munich, Munich, Germany
      name:Department of Obstetrics and Gynaecology, Campus Innenstadt, Ludwig-Maximilians-University Munich, Munich, Germany

External Links {🔗}(155)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.09s.

LINK . SPRINGER . COM {}